Skip to content

Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy

Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02655081
Acronym
IMPACT
Enrollment
48
Registered
2016-01-13
Start date
2015-07-31
Completion date
2016-12-31
Last updated
2017-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

Urinary diversion, Bladder Neoplasm, Nutritional Supplement, Cystectomy

Brief summary

To provide patients with bladder cancer who are scheduled to undergo radical cystectomy with a preoperative high-arginine nutritional supplement. The investigator will measure patient adherence to the regimen, tolerability of the supplement and feasibility of supplementation. Secondary outcome measures will include differences in length of stay and complication rate between groups.

Detailed description

The purpose of this study is to investigate the use of a high-arginine protein supplement prior to surgery for patients undergoing radical cystectomy for treatment of bladder cancer. As many as 50% of patients who undergo radical cystectomy experience a postoperative complication, and poor preoperative nutritional status is known to increase the risk of complications. Preoperative use of a high-arginine protein shake has been shown to reduce the risk of postoperative complications for patients undergoing surgery for colon cancer, and this study seeks to determine whether this is also true for patients undergoing radical cystectomy for bladder cancer. Subjects will drink four protein shakes (Nestle Impact AR) per day for 5-7 days prior to radical cystectomy. Shakes will be provided to patients free of charge. On the date of surgery, subjects will turn in a log of shake consumption. Surgery will then proceed in typical fashion, and no changes will be made to surgery or postoperative care. Clinical outcomes for the first 90 postoperative days will be collected. Patient outcomes will be compared to those of contemporary controls who do not undergo supervised nutritional supplementation. Primary study outcome is to assess safety, tolerability and adherence to supplementation regimen. Secondary outcomes include differences in complication rates and length of postoperative hospital stay between groups.

Interventions

DIETARY_SUPPLEMENThigh arginine nutritional supplement (Nestle's Impact AR)

Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Any adult patient seen at one of the aforementioned UPMC facilities who carries a diagnosis of bladder cancer and is considered a candidate for radical cystectomy for treatment.

Exclusion criteria

* Minors \< 18 years of age, patients not considered surgical candidates, patients who do not go on to undergo radical cystectomy. Patients with Glomerular Filtration Rate (GFR) \< 30 will also be excluded in an attempt to limit protein intake of patients with Stage IV and V Chronic Kidney Disease. Diabetic patients will be allowed to participate.

Design outcomes

Primary

MeasureTime frameDescription
Safety, tolerability and adherence to supplementation regimen.4 monthsInvestigator will report on any adverse events from supplementation as well as patient adherence to regimen.

Secondary

MeasureTime frameDescription
Incidence of 90-day overall and infectious complication rates. I4 monthsInvestigator will compare overall, infectious and wound complication rates between the study group and control group
Length of hospital stay between study group and control group4 monthsThe Investigator will compare the length of hospital stay between study group and control group.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026